GlassScriptPhysician profile
Bassil Aish
NPI 1124015888
$9,451.66
in general payments reported to CMS, 2019-2025
52 companies · $1,909 in 2025
The $1,909 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,033 · 2020: $1,175 · 2021: $2,099 · 2022: $746 · 2023: $1,086 · 2024: $1,404 · 2025: $1,909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,261 · Travel and Lodging: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,261.21 |
| Travel and Lodging | $138.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,800.14 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $744.90 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Lilly USA, LLC | $707.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $627.69 | 2019-2022 | |
| Amarin Pharma, INC. | $608.09 | 2019-2022 | |
| Abbvie INC. | $591.57 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $583.22 | 2019-2025 | Trelegy Ellipta |
| Allergan, INC. | $345.13 | 2019-2020 | |
| Pfizer INC. | $260.92 | 2019-2024 | |
| Eisai INC. | $257.09 | 2020-2022 | |
| Exact Sciences Corporation | $211.06 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $158.01 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novo Nordisk INC | $157.25 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Stryker Corporation | $141.01 | 2019 | |
| Bausch Health US, LLC | $103.30 | 2020-2022 |
Show all 47 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassil Aish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.